Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Sales (2016 - 2025)

Dexcom (DXCM) has disclosed Return on Sales for 16 consecutive years, with 0.21% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 8.0% to 0.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.18%, a 4.0% increase, with the full-year FY2025 number at 0.18%, up 4.0% from a year prior.
  • Return on Sales was 0.21% for Q4 2025 at Dexcom, down from 0.23% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.25% in Q4 2023 to a low of 0.07% in Q1 2023.
  • A 5-year average of 0.14% and a median of 0.13% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -64bps in 2021, then increased 14bps in 2023.
  • Dexcom's Return on Sales stood at 0.08% in 2021, then soared by 39bps to 0.11% in 2022, then skyrocketed by 120bps to 0.25% in 2023, then tumbled by -45bps to 0.14% in 2024, then soared by 56bps to 0.21% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Return on Sales are 0.21% (Q4 2025), 0.23% (Q3 2025), and 0.16% (Q2 2025).